OrthoPediatrics (KIDS) Q2 Revenue Up 16%

OrthoPediatrics (NASDAQ:KIDS) reported mixed Q2 2025 results, with GAAP revenue of $61.1 million slightly missing estimates but growing 15.7% year-over-year, primarily driven by strong U.S., scoliosis, and specialty bracing sales. The company significantly beat adjusted EPS expectations with a narrower loss of ($0.11) and improved Adjusted EBITDA to $4.1 million, up 57.7% year-over-year, reflecting improved operational efficiency. However, GAAP net loss widened to $7.1 million due to increased operating expenses from global sales force expansion and product development investments. Management raised full-year 2025 revenue guidance to $236-$242 million and aims for positive free cash flow by Q4 2025, signaling continued growth investment despite ongoing net losses.

Analysis

OrthoPediatrics (KIDS) reported a mixed second quarter, characterized by strong top-line growth and improving operational efficiency on a non-GAAP basis, but widening GAAP losses due to aggressive investment. Revenue grew 15.7% year-over-year to $61.1 million, driven by robust performance in the U.S. market and standout growth in its Scoliosis (+34% YoY) and Specialty Bracing (+20% YoY) segments, though it fell slightly short of the $61.47 million consensus estimate. The company demonstrated significant progress on profitability from an operational perspective, with adjusted EBITDA growing 57.7% to $4.1 million and a non-GAAP loss per share of ($0.11) substantially beating estimates of ($0.29). However, this was contrasted by a widening GAAP operating loss to $10.6 million from $5.7 million a year prior, a direct result of operating expenses rising 17.6% YoY as the company expands its global sales force and invests in product development. Management's decision to raise full-year 2025 revenue guidance to a range of $236-$242 million, implying 16-18% growth, and reaffirming its adjusted EBITDA target signals confidence in its growth strategy. The stated goal of achieving positive free cash flow by Q4 2025 and breakeven in 2026 frames the current cash burn as a calculated investment toward sustainable profitability, supported by a strong product pipeline with recent FDA approvals.

Key Decisions for Investors

• Investors should weigh the company's strong revenue growth and positive non-GAAP momentum against the near-term pressure of widening GAAP losses, as the raised full-year guidance suggests management's confidence in its investment-led strategy.
• It is critical to monitor the company's ability to control operating expense growth relative to gross profit in the coming quarters, as this will be the primary determinant in achieving its stated goal of positive free cash flow by Q4 2025.
• Key catalysts to track are the commercial success of new products like the 3P Hip System and progress on European regulatory approvals, while risks include high inventory levels and the effectiveness of its significant investment in sales force expansion.